Genelux (GNLX) Gains from Sales and Divestitures (2023 - 2026)
Genelux (GNLX) recorded quarterly Gains from Sales and Divestitures of $29063.0 in Q1 2026, down 90.75% quarter-over-quarter from $314042.0 in Q4 2025.
Genelux (GNLX) Gains from Sales and Divestitures (2023 - 2026) Analysis & Trends
Genelux's Gains from Sales and Divestitures history runs 4 years deep, the most recent figure standing at $29063.0 for Q1 2026.
- In Q1 2026, Gains from Sales and Divestitures changed N/A year-over-year to $29063.0; the TTM figure through Mar 2026 stood at $29063.0 (changed N/A YoY), while the FY2025 annual figure was $314042.0, changed N/A from the prior year.
- Gains from Sales and Divestitures was $29063.0 for Q1 2026 at Genelux, down from $314042.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $314042.0 in Q4 2025 to a low of $1250.0 in Q2 2025.
- Historically, Gains from Sales and Divestitures has averaged $142051.2 across 4 years, with a median of $131267.0 in 2024.
- Biggest YoY gain for Gains from Sales and Divestitures was 83.51% in 2025; the steepest drop was 99.05% in 2025.
- A 4-year view of Gains from Sales and Divestitures shows it stood at $113500.0 in 2023, then soared by 38.16% to $156810.0 in 2024, then surged by 100.27% to $314042.0 in 2025, then plunged by 90.75% to $29063.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $29063.0 (Q1 2026), $314042.0 (Q4 2025), and $287762.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29,063.00 |
| Mar 31, 2026 | 29,063.00 |
| Dec 31, 2025 | 314,042.00 |
| Dec 31, 2025 | 314,042.00 |
| Sep 30, 2025 | 287,762.00 |
| Sep 30, 2025 | 287,762.00 |
| Jun 30, 2025 | 1,250.00 |
| Jun 30, 2025 | 1,250.00 |
| Sep 30, 2024 | 156,810.00 |
| Sep 30, 2024 | 156,810.00 |
| Jun 30, 2024 | 131,267.00 |
| Jun 30, 2024 | 131,267.00 |
| Mar 31, 2024 | 131,267.00 |
| Mar 31, 2024 | 131,267.00 |
| Dec 31, 2023 | 113,500.00 |
| Dec 31, 2023 | 113,500.00 |
| Sep 30, 2023 | 113,500.00 |
| Sep 30, 2023 | 113,500.00 |